Surface Oncology

Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune-evasion. Surface went public in April 2018 (NASDAQ: SURF).

Headquarters Cambridge, MA
Pipeline Preclinical
Twitter @SurfaceOncology